Astellas To Market Pain Patch Of NeurogesX Of U.S.
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma has agreed to market U.S.-based NeurogesX's patch for relieving pain in Europe, Africa and the Middle East. The drug is Qutenza (capsaicin), which has European Union approval, but is not yet approved in the United States. Under the agreement, Astellas is to pay NeurogesX $42 million upfront for marketing rights. The drug patch is expected to be launched in the first half of next year. (Click here for more